Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05507723

Tight Control of Gouty Arthritis Compared to Usual Care

Led by University of Edinburgh · Updated on 2026-04-08

125

Participants Needed

1

Research Sites

185 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Gout is caused by a reaction to urate crystals that results in attacks of severe joint pain. Medicines that lower urate levels can prevent gout flares, however it takes time for this benefit to be felt, and paradoxically starting treatment with large doses of urate lowering treatment risks provoking attacks of gout. Medical guidelines disagree on the best way to overcome these challenges with many recommending medicine dose adjustment based on regular urate testing but a general practice guideline suggesting more simply increasing the medicine dose in those patients that continue to suffer flares. In reality most patients are not treated at all, and many of those that are treated never receive an effective dose of treatment. We have developed a supported self-management approach to gout in which patients monitor their own urate levels using a finger prick test, and then receive advice on adjusting their treatment dose to achieve target urate levels through a smartphone app (Gout SMART). A trial of this approach has shown that it results in much better control of urate levels after 6 months than usual care, and suggests that it also leads to fewer flares. We would now like to confirm that this approach is effective in reducing flares of gout over 2 years by randomising patients to either treatment-to-target urate using our self-monitoring approach, or to usual care.

CONDITIONS

Official Title

Tight Control of Gouty Arthritis Compared to Usual Care

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Provide informed consent
  • Age 18 years or older
  • Have had at least one gout flare in the previous 12 months
  • Confirmed clinical diagnosis of gout according to ACR/EULAR criteria
  • Serum urate level greater than 0.36 mmol/L
  • Own a smartphone and able to install the GoutSMART application
Not Eligible

You will not qualify if you...

  • Unable to provide consent
  • On maximum urate lowering therapy or unable to increase therapy due to intolerance or adverse reaction to allopurinol or febuxostat
  • Have end stage renal failure or received a transplant
  • Currently prescribed medications that interact with xanthine oxidase inhibitors such as azathioprine or mercapto-purine

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

NHS Lothian

Edinburgh, United Kingdom

Actively Recruiting

Loading map...

Research Team

P

Philip L Riches, FRCP, PhD

CONTACT

J

Jo-Anne Robertson

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

HEALTH_SERVICES_RESEARCH

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Tight Control of Gouty Arthritis Compared to Usual Care | DecenTrialz